119367-89-4Relevant academic research and scientific papers
COMPOUNDS AND METHODS FOR USE IN TREATING NEOPLASIA AND CANCER
-
Page/Page column 63, (2013/03/26)
The present invention relates to a novel method for the treatment of neoplasia, including cancer and other diseases and conditions in humans and mammals. More particularly, in preferred aspects, the present invention provides a method for the use of novel compounds for the treatment of neoplasia, hyperproliferative cell growth including psoriasis, restenosis following cardiovascular surgery, hyperplasia, including renal hyperplasia, chronic inflammatory diseases including rheumatoid and osteoarthritis, among others.
Amide-modified prenylcysteine based Icmt inhibitors: Structure-activity relationships, kinetic analysis and cellular characterization
Majmudar, Jaimeen D.,Hodges-Loaiza, Heather B.,Hahne, Kalub,Donelson, James L.,Song, Jiao,Shrestha, Liza,Harrison, Marietta L.,Hrycyna, Christine A.,Gibbs, Richard A.
, p. 283 - 295 (2012/02/17)
Human protein isoprenylcysteine carboxyl methyltransferase (hIcmt) is the enzyme responsible for the α-carboxyl methylation of the C-terminal isoprenylated cysteine of CaaX proteins, including Ras proteins. This specific posttranslational methylation event has been shown to be important for cellular transformation by oncogenic Ras isoforms. This finding led to interest in hIcmt inhibitors as potential anti-cancer agents. Previous analog studies based on N-acetyl-S-farnesylcysteine identified two prenylcysteine-based low micromolar inhibitors (1a and 1b) of hIcmt, each bearing a phenoxyphenyl amide modification. In this study, a focused library of analogs of 1a and 1b was synthesized and screened versus hIcmt, delineating structural features important for inhibition. Kinetic characterization of the most potent analogs 1a and 1b established that both inhibitors exhibited mixed-mode inhibition and that the competitive component predominated. Using the Cheng-Prusoff method, the K i values were determined from the IC50 values. Analog 1a has a KIC of 1.4 ± 0.2 μM and a KIU of 4.8 ± 0.5 μM while 1b has a KIC of 0.5 ± 0.07 μM and a KIU of 1.9 ± 0.2 μM. Cellular evaluation of 1b revealed that it alters the subcellular localization of GFP-KRas, and also inhibits both Ras activation and Erk phosphorylation in Jurkat cells.
Intramolecular Generation of Oxonium Ylides from Functionalized Arylcarbenes
Kirmse, Wolfgang,Kund, Klaus
, p. 1465 - 1473 (2007/10/02)
Arylcarbenes carrying alkoxyalkyl groups in the ortho position have been generated by flash pyrolysis and photolysis of appropriate tosylhydrazone sodium salts.In the gas phase and in a aprotic solvents, interaction of the carbenes with the lone electron pairs of oxygen competes efficiently with insertion into C-H bonds.Both five- and six-membered cyclic oxonium ylides have been generated.The ylides 23, 37, 61b, and 74 undergo 1,2 shifts of benzyl groups with ease, even if ring contraction to highly strained benzocyclobutenes is involved (23, 74).The oxonium ylides37 and 61b strongly prefer the nonconcerted Stevens rearrangement to the sigmatropic Sommelet rearrangement, in contrast to analogous ammonium ylides.Alkyl shifts occur to a very minor extent, if at all.Evidence is presented that alcohols intercept both the carbenes and the oxonium ylides.Protonation of the ylides leads to cyclic oxonium ions, which undergo nucleophilic cleavage of the C-O bonds.Acid catalyzed decomposition of the appropriate diazo compounds gives rise to six-membered, but not to five-membered, cyclic oxonium ions, thus confirming the different intramolecular reactivities of arylcarbenes and benzyl cations.The efficiency of carbene interception increases with increasing acidity of the medium, suggesting nucleophilic behavior (protonation) of the arylcarbenes.
